Matches in Wikidata for { <http://www.wikidata.org/entity/Q57166802> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- Q57166802 description "article" @default.
- Q57166802 description "im August 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q57166802 description "wetenschappelijk artikel" @default.
- Q57166802 description "наукова стаття, опублікована в серпні 2018" @default.
- Q57166802 name "The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data" @default.
- Q57166802 name "The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data" @default.
- Q57166802 type Item @default.
- Q57166802 label "The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data" @default.
- Q57166802 label "The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data" @default.
- Q57166802 prefLabel "The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data" @default.
- Q57166802 prefLabel "The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data" @default.
- Q57166802 P1104 Q57166802-1BA11621-18F3-48CD-B47E-EF0623DE2177 @default.
- Q57166802 P1433 Q57166802-3A36F475-217C-457A-9F19-69FAD64100DC @default.
- Q57166802 P1476 Q57166802-E80DA66E-5940-44E1-8CA1-0C900C098C49 @default.
- Q57166802 P2093 Q57166802-067399C8-CA74-45CF-A690-5970916FAF30 @default.
- Q57166802 P2093 Q57166802-0DD0B336-F08D-4DE1-B3AB-E9DE3B3725DB @default.
- Q57166802 P2093 Q57166802-0E09F2F1-46AB-4E29-A340-3B6A8EF769DB @default.
- Q57166802 P2093 Q57166802-420C2ACE-9E7C-4DCE-A070-DD51E3B078C3 @default.
- Q57166802 P2093 Q57166802-61709C3F-C233-4A6A-8D5D-5632ADD548D8 @default.
- Q57166802 P2093 Q57166802-A3B1FB7F-E7C1-4A57-A145-58F50421F434 @default.
- Q57166802 P2093 Q57166802-B04F8DE9-E0C2-4F73-B3C3-0C2C0AECEB75 @default.
- Q57166802 P2093 Q57166802-BD429EB4-AE23-4BA6-A590-D13A35201935 @default.
- Q57166802 P2093 Q57166802-D8BBB17D-52BC-4834-A9C0-6FE550457D5E @default.
- Q57166802 P2093 Q57166802-EE386A83-1C5D-45D4-9E50-03D003AA0969 @default.
- Q57166802 P304 Q57166802-432BA24C-66EE-4DBE-86A4-87890E4DFF1D @default.
- Q57166802 P31 Q57166802-35DA034F-380C-4C13-89C6-08B063A3592B @default.
- Q57166802 P356 Q57166802-AC9D24D0-BF82-4D78-9649-4FA861C1C556 @default.
- Q57166802 P407 Q57166802-BA9DF198-4203-4AE7-8862-B593607EC13A @default.
- Q57166802 P478 Q57166802-06B12E03-A945-4A2B-BFE9-7D2232526819 @default.
- Q57166802 P50 Q57166802-4DDA4773-24F1-4075-B198-CF2A0485DCC2 @default.
- Q57166802 P577 Q57166802-67CC6199-7115-4743-BD38-091CE0EB4502 @default.
- Q57166802 P698 Q57166802-1E9CD3AD-09E8-4881-B814-C5A9CEC19C57 @default.
- Q57166802 P921 Q57166802-62adc338-bd54-4437-b75f-b8d9c91052e1 @default.
- Q57166802 P921 Q57166802-83FA63B4-0381-4052-BCCC-95D1DCFDEBDD @default.
- Q57166802 P921 Q57166802-D9A746DD-4AC7-4154-9F83-F71CB28282CB @default.
- Q57166802 P356 J.PNPBP.2018.08.033 @default.
- Q57166802 P698 30172739 @default.
- Q57166802 P1104 "+7" @default.
- Q57166802 P1433 Q15616665 @default.
- Q57166802 P1476 "The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data" @default.
- Q57166802 P2093 "Ariel Graff-Guerrero" @default.
- Q57166802 P2093 "Eric Plitman" @default.
- Q57166802 P2093 "Fernando Caravaggio" @default.
- Q57166802 P2093 "Hiroyuki Uchida" @default.
- Q57166802 P2093 "Julia Kim" @default.
- Q57166802 P2093 "Jun Ku Chung" @default.
- Q57166802 P2093 "Miracle Ozzoude" @default.
- Q57166802 P2093 "Philip Gerretsen" @default.
- Q57166802 P2093 "Shinichiro Nakajima" @default.
- Q57166802 P2093 "Yusuke Iwata" @default.
- Q57166802 P304 "207-213" @default.
- Q57166802 P31 Q13442814 @default.
- Q57166802 P356 "10.1016/J.PNPBP.2018.08.033" @default.
- Q57166802 P407 Q1860 @default.
- Q57166802 P478 "89" @default.
- Q57166802 P50 Q50531776 @default.
- Q57166802 P577 "2018-08-30T00:00:00Z" @default.
- Q57166802 P698 "30172739" @default.
- Q57166802 P921 Q170304 @default.
- Q57166802 P921 Q26989040 @default.
- Q57166802 P921 Q41112 @default.